• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

孟鲁司特钠鼻喷剂的制剂开发及体外评价。

Montelukast nasal spray: formulation development and in vitro evaluation.

机构信息

a Department of Pharmaceutical Technology, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Songkhla , Thailand.

b Nanotec-PSU Excellence Center on Drug Delivery System, Faculty of Pharmaceutical Sciences , Prince of Songkla University , Hat Yai , Songkhla , Thailand.

出版信息

Pharm Dev Technol. 2019 Apr;24(4):494-503. doi: 10.1080/10837450.2018.1514523. Epub 2018 Sep 27.

DOI:10.1080/10837450.2018.1514523
PMID:30124348
Abstract

OBJECTIVES

The aim of this study was to evaluate potential development of montelukast sodium (MTS) as a nasal spray.

MATERIALS AND METHODS

The formulations were prepared using hydroxypropyl cellulose (HPC) and carbomer 940 (C940). The prepared formulations were evaluated for clarity, pH, hydrodynamic size, zeta potential, viscosity, contact angle, surface tension, droplet size distribution, muco-adhesiveness, drug release, and stability. The suitable formulations were also assessed for their effects on nasal epithelial cells.

RESULTS AND DISCUSSION

At room temperature (25 °C), the formulation containing 0.01% w/v C940 exhibited suitable viscosity and rheological properties. Spray droplets were in ranges of 10-40 µm, which are suitable for nasal administration. The works of adhesion of the formulations containing HPC or C940 were in the range of 0.8-4.0 and 0.2-27 µJ, respectively. In addition, the formulation containing 0.01% w/v C940 and the 0.5-15 µg/50 µL concentrations of MTS showed no signs of cytotoxicity and did not open the tight junction of nasal epithelial cells.

CONCLUSION

The formulated MTS nasal spray is ideal for nasal administration for the treatment of allergic rhinitis. The formulation containing 0.01% w/v C940 had no toxicity nor alteration on the tight junction of nasal epithelial cells.

摘要

目的

本研究旨在评估孟鲁司特钠(MTS)作为鼻腔喷雾剂的潜在开发前景。

材料与方法

采用羟丙纤维素(HPC)和卡波姆 940(C940)制备制剂。对制备的制剂进行澄清度、pH 值、水动力粒径、zeta 电位、黏度、接触角、表面张力、液滴粒径分布、黏膜黏附性、药物释放和稳定性评估。还对合适的制剂进行了对鼻上皮细胞影响的评估。

结果与讨论

在室温(25°C)下,含有 0.01%w/v C940 的制剂表现出适宜的黏度和流变学性质。喷雾液滴在 10-40µm 范围内,适合鼻腔给药。含有 HPC 或 C940 的制剂的附着功分别在 0.8-4.0 和 0.2-27µJ 范围内。此外,含有 0.01%w/v C940 的制剂和 0.5-15µg/50µL 浓度的 MTS 未显示出细胞毒性迹象,也未打开鼻上皮细胞的紧密连接。

结论

所配制的 MTS 鼻腔喷雾剂非常适合治疗过敏性鼻炎的鼻腔给药。含有 0.01%w/v C940 的制剂无毒性,也不会改变鼻上皮细胞的紧密连接。

相似文献

1
Montelukast nasal spray: formulation development and in vitro evaluation.孟鲁司特钠鼻喷剂的制剂开发及体外评价。
Pharm Dev Technol. 2019 Apr;24(4):494-503. doi: 10.1080/10837450.2018.1514523. Epub 2018 Sep 27.
2
Effects of montelukast on human nasal mucosa.孟鲁司特对人鼻黏膜的影响。
Eur Arch Otorhinolaryngol. 2019 Mar;276(3):761-765. doi: 10.1007/s00405-018-05274-8. Epub 2019 Jan 2.
3
Inhibitory effects of Montelukast on mediator release by nasal epithelial cells from asthmatic subjects with or without allergic rhinitis.孟鲁司特钠对伴有或不伴变应性鼻炎的哮喘患者鼻黏膜上皮细胞介质释放的抑制作用。
Respir Med. 2013 Dec;107(12):1859-65. doi: 10.1016/j.rmed.2013.09.006. Epub 2013 Sep 18.
4
Preparation and In Vitro Evaluation of Montelukast Sodium-Loaded 3D Printed Orodispersible Films for the Treatment of Asthma.孟鲁司特钠载 3D 打印口腔速溶膜的制备及体外评价用于哮喘治疗。
AAPS PharmSciTech. 2024 Sep 17;25(7):218. doi: 10.1208/s12249-024-02938-z.
5
Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats.新型孟鲁司特钠载药口服混悬剂在大鼠体内与市售颗粒剂具有生物等效性。
Arch Pharm Res. 2016 Apr;39(4):539-546. doi: 10.1007/s12272-015-0664-x. Epub 2016 Mar 17.
6
Evaluation of different parameters that affect droplet-size distribution from nasal sprays using the Malvern Spraytec.使用马尔文喷雾技术评估影响鼻喷雾剂液滴尺寸分布的不同参数。
J Pharm Sci. 2004 Jul;93(7):1725-42. doi: 10.1002/jps.20090.
7
Novel nano-cellulose excipient for generating non-Newtonian droplets for targeted nasal drug delivery.用于生成非牛顿液滴以实现靶向鼻腔给药的新型纳米纤维素辅料。
Drug Dev Ind Pharm. 2017 Oct;43(10):1729-1733. doi: 10.1080/03639045.2017.1339078. Epub 2017 Jun 21.
8
Impact of Food and Drink Administration Vehicles on Paediatric Formulation Performance Part 2: Dissolution of Montelukast Sodium and Mesalazine Formulations.食品和饮料管理车辆对儿科配方性能的影响 第 2 部分:孟鲁司特钠和美沙拉嗪配方的溶解。
AAPS PharmSciTech. 2020 Oct 15;21(7):287. doi: 10.1208/s12249-020-01815-9.
9
[Clinical evaluation of Montelukast plus Budesonide nasal spray and Desloratadine citrate disodium in treating moderate and severe persistent allergic rhinitis].孟鲁司特联合布地奈德鼻喷雾剂及枸橼酸地氯雷他定二钠治疗中重度持续性变应性鼻炎的临床评价
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi. 2015 Dec;29(23):2041-3.
10
In Vivo Predictive Dissolution Testing of Montelukast Sodium Formulations Administered with Drinks and Soft Foods to Infants.婴儿服用饮料和软食时给予的孟鲁司特钠制剂的体内预测溶出度测试。
AAPS PharmSciTech. 2020 Oct 13;21(7):282. doi: 10.1208/s12249-020-01825-7.

引用本文的文献

1
Formulation of nasal analgesic sprays with diclofenac sodium, ibuprofen, paracetamol, and evaluation of toxicity.双氯芬酸钠、布洛芬、对乙酰氨基酚鼻腔镇痛喷雾剂的配方及毒性评估。
Sci Prog. 2024 Oct-Dec;107(4):368504241304200. doi: 10.1177/00368504241304200.
2
Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator.孟鲁司特作为一种病毒灭活剂抑制 HCoV-OC43 感染。
Viruses. 2022 Apr 21;14(5):861. doi: 10.3390/v14050861.
3
Design and Application in Delivery System of Intranasal Antidepressants.鼻内抗抑郁药递送系统的设计与应用
Front Bioeng Biotechnol. 2020 Dec 21;8:626882. doi: 10.3389/fbioe.2020.626882. eCollection 2020.
4
Modulation of Allergic Inflammation in the Nasal Mucosa of Allergic Rhinitis Sufferers With Topical Pharmaceutical Agents.局部用药对变应性鼻炎患者鼻黏膜变应性炎症的调节作用
Front Pharmacol. 2019 Mar 29;10:294. doi: 10.3389/fphar.2019.00294. eCollection 2019.
5
Effects of montelukast on human nasal mucosa.孟鲁司特对人鼻黏膜的影响。
Eur Arch Otorhinolaryngol. 2019 Mar;276(3):761-765. doi: 10.1007/s00405-018-05274-8. Epub 2019 Jan 2.